The Human collagen, type I, alpha 1 (COL1A1) ELISA Kit quantifies COL1A1 in multiple biological solutions, including serum, plasma, cell culture supernates, or tissue homogenates. It is not intended for diagnostic use. This assay kit was designed and optimized for signal transduction research use in humans. The kit has undergone rigorous quality control in multiple parameters, including sensitivity, specificity, precision, linearity, recovery, and inter-batch difference. Refer to the product instructions for more details.
This assay employs the quantitative sandwich enzyme immunoassay technique, in which COL1A1 in the samples or standards are sandwiched between pre-coated COL1A1 antibody and Biotin-conjugated COL1A1 antibody. HRP-avidin is then added into the wells. Following a wash to remove any unbound reagent, the TMB substrate solution is added to the wells and color develops in proportion to the amount of COL1A1 bound in the initial step. The color development is stopped upon adding the stop solution, and the intensity of the color is measured at 450 nm via a microplate reader. The levels of COL1A1 in the samples can be determined by referring to the O.D. (optical density) of the samples to the standard curve.
COL1A1 is the major component of type I collagen. It is made up of three conservative domains: a von Willebrand factor type C (vWFC) domain, a collagen triple-helix repeat, and a fibrillar collagen C-terminal domain (COLF). Studies of COL1A1 have primarily focused on osteogenesis, osteoporosis, and bone diseases. Recent studies have shown that overexpression of COL1A1 is detected in various tumor tissues and cells. Zheying Zhang etc. demonstrated that COL1A1 functions as an oncogene in colorectal cancer (CRC) progression and is related to metastasis. COL1A1 upregulation in patients with CRC indicated poorer outcomes and disease-free survival (DFS).
